Bolt Biotherapeutics (NASDAQ:BOLT) Issues Quarterly Earnings Results, Misses Expectations By $1.18 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) announced its earnings results on Tuesday. The company reported ($4.57) EPS for the quarter, missing the consensus estimate of ($3.39) by ($1.18), FiscalAI reports. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%.

Bolt Biotherapeutics Trading Down 0.3%

Shares of NASDAQ:BOLT traded down $0.01 during midday trading on Tuesday, reaching $3.98. The company’s stock had a trading volume of 10,182 shares, compared to its average volume of 24,902. Bolt Biotherapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $7.20. The company has a debt-to-equity ratio of 0.98, a quick ratio of 3.51 and a current ratio of 3.51. The firm has a 50 day moving average price of $4.17 and a two-hundred day moving average price of $4.65. The firm has a market capitalization of $7.65 million, a price-to-earnings ratio of -0.24 and a beta of 1.18.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC lifted its stake in Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after buying an additional 2,448 shares during the period. Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $85,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth approximately $89,000. Finally, Renaissance Technologies LLC increased its stake in shares of Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after acquiring an additional 26,400 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BOLT. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Rodman & Renshaw began coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They set a “buy” rating and a $22.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $34.67.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.